sagent pharmaceuticals inc (SGNT) Key Developments
Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President
Apr 16 15
Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.
Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors
Apr 16 15
Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.
Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP
Apr 13 15
Sagent Pharmaceuticals, Inc. announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation. The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresS packaging and labeling, designed to help reduce medication errors.
Sagent Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Fiscal Year of 2015
Mar 26 15
Sagent Pharmaceuticals, Inc. reiterated revenue guidance for the fiscal year of 2015. The company reiterated its 2015 revenue guidance range of $325 million to $375 million.
Sagent Pharmaceuticals Announces Management Changes
Mar 26 15
Sagent Pharmaceuticals, Inc. announced that Jeffrey Yordon, Chairman and Chief Executive Officer, has informed the Board of his decision to retire from the Company. He will remain a member of the Board. Frank Kung, Ph.D., a well-regarded industry executive and a member of Sagent's Board since 2006, has been named Chairman. The Board will immediately begin the search for a new CEO. In the interim, the Board has formed an Executive Management Committee to lead the Company. Sagent announced that James Hussey, who served as the Company's President, has decided to leave the Company.